Table 2.
Characteristics of the study population (mean±SEM)
| Vertebral fracture N=30 |
Control N=30 |
P-value | |
|---|---|---|---|
| Age | 69 ± 1 | 69 ± 1 | 0.98 |
| Race | |||
| % Caucasian | 86 | 93 | 0.86 |
| % African American | 4 | 3 | |
| % Other | 10 | 4 | |
| Ethnicity | |||
| % Hispanic | 28 | 5 | 0.01 |
| % Non-Hispanic | 72 | 95 | |
| BMI (kg/m2) | 27 ± 1 | 26 ± 1 | 0.35 |
| Years since menopause | 18 ± 2 | 20 ± 1 | 0.56 |
| Family history of osteoporosis by BMD (%) | 54 | 45 | 0.34 |
| Family history of fracture (%) | 27 | 33 | 0.23 |
| Tobacco use – | |||
| Never (%) | 55 | 70 | 0.10 |
| Former (%) | 41 | 30 | |
| Current (%) | 4 | 0 | |
| Alcohol use (beverages per day) | 0.4 ± 0.1 | 1.1 ± 0.3 | 0.02 |
| Calcium supplements – total daily dose (mg) | 730 ± 136 | 1025± 102 | 0.14 |
| Vitamin D supplements – total daily dose (IU) | 632 ± 386 | 190 ± 40 | 0.29 |
| Hormone replacement therapy – Past (%) | 39 | 61 | 0.13 |
| –Current (%) | 15 | 9 | 0.96 |
| Bisphosphonatesa - Past (%) | 7 | 3 | 0.55 |
| Current (%) | 10 | 3 | 0.31 |
| Raloxifene (%) | 11 | 4 | 0.40 |
| Thyroxine (%) | 18 | 35 | 0.17 |
| SSRIs (%) | 11 | 13 | 0.80 |
| Inhaled glucocorticoids (%) | 0 | 4 | 0.27 |
a
Prior bisphosphonate use limited to <1 yr